Kadmon eyes $15.5K pricetag and August debut for new transplant rejection med Rezurocknews2021-07-19T13:40:50+00:00July 19th, 2021|Fierce Pharma|
Merck’s next-gen pneumococcal shot scores FDA nod, setting up high-stakes clash with rival Pfizernews2021-07-19T13:21:32+00:00July 19th, 2021|Fierce Pharma|
In a first, Micron starts testing microneedle vaccine in kidsnews2021-07-19T10:30:35+00:00July 19th, 2021|Fierce Pharma|
Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. marketnews2021-07-19T10:26:29+00:00July 19th, 2021|Fierce Pharma|
Eli Lilly opens Olympic Games with first corporate ad—and a reality check on the state of the U.S. health systemnews2021-07-16T21:45:08+00:00July 16th, 2021|Fierce Pharma|
Lyme diagnostic maker Quidel pushes rapid testing in summer camp-focused campaignnews2021-07-16T19:33:55+00:00July 16th, 2021|Fierce Pharma|
Kadmon’s Rezurock scores surprise FDA nod in chronic graft-versus-host-diseasenews2021-07-16T19:24:54+00:00July 16th, 2021|Fierce Pharma|
Johnson & Johnson takes to Twitter to expand its network of storytelling patientsnews2021-07-16T18:36:35+00:00July 16th, 2021|Fierce Pharma|
Merck KGaA’s U.S. unit launches first-ever TV ad with MS drug Mavenclad in the spotlightnews2021-07-16T18:00:39+00:00July 16th, 2021|Fierce Pharma|
Bristol Myers Squibb’s Opdivo and Yervoy combo falls short in first-line squamous head and neck cancernews2021-07-16T15:38:00+00:00July 16th, 2021|Fierce Pharma|
